Relationship Between Contrast Media Volume and Tube Voltage in CT for Optimal Liver Enhancement, Based on Body Weight.
NCT ID: NCT03735706
Last Updated: 2020-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
245 participants
INTERVENTIONAL
2018-12-13
2019-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recent publications suggested individualization of injection protocols that can be based on either total body weight (TBW) or lean body weight (LBW) \[6-9\]. In the investigators department an injection protocol based on TBW is currently used.
Besides the CM injection parameters, scanner parameters are of influence on the attenuation as well. Because of recent technical developments it became possible to reach a good image quality (IQ) at lower tube voltages \[10\]. When the x-ray output comes closer to the 33 keV k-edge of Iodine, attenuation increases. In short, decreasing the tube voltage increases the attenuation of iodine. Scanning at a lower tube voltage therefore gives rise to even lower CM volumes. Lastly, it would be revolutionary to accomplish a liver enhancement that is homogenous, sufficient for lesion detection and comparable between patients and in the same patients, regardless of weight and scanner settings used.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Contrast Agent Administration Protocols
NCT04300972
Contrast Media Temperature and Patient Comfort in CT of the Abdomen
NCT04249479
Volume CT of the Wrist and Carpus After Trauma
NCT01857570
Risk Factors and Computed Tomography Findings in COVID-19.
NCT04577105
Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations
NCT06965790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The parenchymal enhancement depends on patient, CT scanner and CM factors. Weight, height, cardiac output, age, gender, venous access, breath-holding, renal function and comorbidity all fall under patient factors \[8\]. Recently much research showed preferable outcomes for individualized CM injection protocols, in which the contrast bolus is adapted to patient TBW, LBW or body surface area (BSA) \[6, 7, 9, 13-15\]. In a recent feasibility study in the department of the investigators, the attenuation of the liver parenchyma was evaluated. Results showed that a body weight adapted CM injection protocol resulted in more homogeneous liver enhancement compared to a fixed CM dose (not published yet).
With recent technological developments in X-ray tube technology it became possible to use lower tube voltages. As a result making it possible to perform scans with a sufficient image quality (IQ) and a low tube voltage and therefore a lower radiation dose \[10\]. Another advantage lies in the fact that reducing the tube voltage, approaching 33 keV k-edge of iodine, results in an increase in attenuation of the iodine. The new technological developments make it possible to reduce the radiation dose and CM volume at the same time. So reducing the tube voltage, makes it also possible to reduce the CM volume.
As recommended by the supplier, it is possible to calculate the total iodine load (TIL) that can be spared with the use of lower kV settings \[16\]. A reduction of 10 kV should result in a 10% reduction in CM volume. Reducing the tube voltage from 120 to 90 kV should therefore lead to a 30% reduction in CM volume. As mentioned before it is preferred to use an individualized CM injection protocol based on TBW or LBW. For this study, this theory is adapted to the concept of TBW. The following indicates which dosing factors should be used for each kV setting, based on the recommendations mentioned in the above.
120 kV -\> 0.521 g I/kg 110 kV -\> 0.469 g I/kg 100 kV -\> 0.417 g I/kg 90 kV -\> 0.365 g I/kg 80 kV -\> 0.313 g I/kg 70 kV -\> 0.261 g I/kg
The aim of present study is to investigate if adapting the dosing factor based on TBW and therefore the CM volume to the tube voltage used, results in a more homogeneous liver enhancement. The hypothesis is to find a more homogeneous enhancement between patients and in the same patient, regardless of body composition and tube voltage used.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
TRIPLE
The blinding and randomization process will be conducted by Clinical Trial Centre Maastricht (CTCM, www.CTCM.nl) with a randomization program (ALEA) designed for usage of different techniques.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group - 120 kV - 0.521 g I/kg
Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.
The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV.
Unenhanced slice
One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
Weight
A weighing scale is used to measure a patients body weight right before the scan.
90 kV - 0.521 g I/kg
Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.
A radiation dose reduction from 120 to 90 kV.
The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1.
Radiation dose reduction
The radiation dose is is different between groups
Unenhanced slice
One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
Weight
A weighing scale is used to measure a patients body weight right before the scan.
100 kV - 0.417 g I/kg
Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.
The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg.
Radiation dose reduction
The radiation dose is is different between groups
Contrast media volume reduction
Contrast media volume is different between groups
Unenhanced slice
One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
Weight
A weighing scale is used to measure a patients body weight right before the scan.
90 kV - 0.365 g I/kg
Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.
The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg.
Radiation dose reduction
The radiation dose is is different between groups
Contrast media volume reduction
Contrast media volume is different between groups
Unenhanced slice
One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
Weight
A weighing scale is used to measure a patients body weight right before the scan.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiation dose reduction
The radiation dose is is different between groups
Contrast media volume reduction
Contrast media volume is different between groups
Unenhanced slice
One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
Weight
A weighing scale is used to measure a patients body weight right before the scan.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients ≥ 18 years and competent to sign an informed consent
Exclusion Criteria
* Pregnancy
* Renal insufficiency (defined as Glomerular Filtration Rate (GFR) \< 30 mL/min/1,73m2 \[Odin protocol 004720\])
* Iodine allergy (Odin protocol 022199)
* Age \<18 years
* Absence of informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joachim Wildberger, Professor
Role: PRINCIPAL_INVESTIGATOR
Maastricht University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MUMC+
Maastricht, Limburg, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL66971.068.18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.